Please enable JavaScript to continue using this application.

Compare $CYTK vs $SYRE | Chartloom

Compare

$CYTK vs $SYRE

Cytokinetics Inc · Spyre Therapeutics Inc

CYTK

Cytokinetics Inc

SYRE

Spyre Therapeutics Inc

Compare $CYTK vs $SYRE

Comparing Cytokinetics Inc and Spyre Therapeutics Inc

CYTKCytokinetics Inc

SYRESpyre Therapeutics Inc

CYTKCytokinetics Inc

Market cap

$8.53B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

33.61x

Rev growth (TTM)

-21.1%

YTD performance

1.9%

52W performance

3.4%

FCF yield

-6.8%

SYRESpyre Therapeutics Inc

Market cap

$7.44B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

180.2%

52W performance

384.7%

FCF yield

-2.8%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

CYTK

SYRE

Detailed metrics comparison

CYTK

Cytokinetics Inc

SYRE

Spyre Therapeutics Inc

Market Cap

CYTK$8.53B

SYRE$7.44B

Enterprise Value

CYTK$9.42B

SYRE$7.28B

Price

CYTK$62.91

SYRE$85.69

P/E Ratio

CYTKN/A

SYREN/A

P/S Ratio

CYTK126.04x

SYRE6,680.42x

EV/Sales

CYTK139.22x

SYRE0.00x

EV/EBITDA

CYTK1,193.30x

SYRE0.00x

P/B Ratio

CYTK83.67x

SYRE7.46x

P/FCF Ratio

CYTKN/A

SYREN/A

EV/FCF

CYTK-16.22x

SYRE-34.84x

PEG Ratio

CYTKN/A

SYREN/A

Forward P/E (NTM)

CYTKN/A

SYREN/A

Forward P/S (NTM)

CYTK33.61x

SYREN/A

Revenue (TTM)

CYTK$68M

SYRE$0

Revenue Growth (YoY)

CYTK-21.1%

SYREN/A

Forward Rev Growth

CYTK183.7%

SYRE231.1%

Gross Margin (TTM)

CYTK58.9%

SYRE0.0%

Operating Margin (TTM)

CYTK0.0%

SYRE0.0%

EBITDA Margin (TTM)

CYTK-1027.6%

SYRE0.0%

Net Margin (TTM)

CYTK-1321.1%

SYRE0.0%

FCF Margin (TTM)

CYTK-858.2%

SYREN/A

Net Income (TTM)

CYTK$-894M

SYRE$-179M

FCF (TTM)

CYTK$-581M

SYRE$-209M

EPS (TTM)

CYTK-$6.77

SYRE-$2.11

ROE (TTM)

CYTK-13119.0%

SYRE-2432.0%

ROA (TTM)

CYTK-5902.0%

SYRE-2223.0%

ROIC (TTM)

CYTK-1872.0%

SYRE-2432.0%

Cash

CYTK$255M

SYRE$162M

Debt

CYTK$1.15B

SYRE$0

Net Cash/Debt

CYTK$-892M

SYRE$162M

Current Ratio (TTM)

CYTK6.66x

SYRE18.53x

Quick Ratio (TTM)

CYTK6.56x

SYRE18.09x

Debt/Equity (TTM)

CYTK6.01x

SYRE0.00x

Debt/Assets (TTM)

CYTK0.0%

SYRE0.0%

Interest Coverage (TTM)

CYTKN/A

SYREN/A

Net Debt/EBITDA (TTM)

CYTK0.00x

SYRE0.00x

Beta

CYTK0.42

SYRE3.19

52W Performance

CYTK3.4%

SYRE384.7%

YTD Performance

CYTK1.9%

SYRE180.2%

% from 52W High

CYTK-28.8%

SYRE-22.2%

% from 52W Low

CYTK15.9%

SYRE385.5%

Asset Turnover (TTM)

CYTK0.04x

SYRE0.01x

FCF Yield (TTM)

CYTK-6.8%

SYRE-2.8%

Earnings Yield (TTM)

CYTK-10.5%

SYRE-2.4%

Dividend Yield (TTM)

CYTKN/A

SYREN/A

Rule of 40

CYTK-879.2

SYRE0.0

EV/GP/RG

CYTK0.73

SYREN/A

Ticker research

View CYTK research View SYRE research

Metric	CYTK Cytokinetics Inc	SYRE Spyre Therapeutics Inc
Market & Valuation
Market Cap	$8.53B	$7.44B
Enterprise Value	$9.42B	$7.28B
Price	$62.91	$85.69
P/E Ratio	N/A	N/A
P/S Ratio	126.04x	6,680.42x
EV/Sales	139.22x	0.00x
EV/EBITDA	1,193.30x	0.00x
P/B Ratio	83.67x	7.46x
P/FCF Ratio	N/A	N/A
EV/FCF	-16.22x	-34.84x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	33.61x	N/A
Revenue & Growth
Revenue (TTM)	$68M	$0
Revenue Growth (YoY)	-21.1%	N/A
Forward Rev Growth	183.7%	231.1%
Profitability
Gross Margin (TTM)	58.9%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-1027.6%	0.0%
Net Margin (TTM)	-1321.1%	0.0%
FCF Margin (TTM)	-858.2%	N/A
Net Income (TTM)	$-894M	$-179M
FCF (TTM)	$-581M	$-209M
EPS (TTM)	-$6.77	-$2.11
ROE (TTM)	-13119.0%	-2432.0%
ROA (TTM)	-5902.0%	-2223.0%
ROIC (TTM)	-1872.0%	-2432.0%
Financial Health
Cash	$255M	$162M
Debt	$1.15B	$0
Net Cash/Debt	$-892M	$162M
Current Ratio (TTM)	6.66x	18.53x
Quick Ratio (TTM)	6.56x	18.09x
Debt/Equity (TTM)	6.01x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.42	3.19
52W Performance	3.4%	384.7%
YTD Performance	1.9%	180.2%
% from 52W High	-28.8%	-22.2%
% from 52W Low	15.9%	385.5%
Efficiency & Yields
Asset Turnover (TTM)	0.04x	0.01x
FCF Yield (TTM)	-6.8%	-2.8%
Earnings Yield (TTM)	-10.5%	-2.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-879.2	0.0
EV/GP/RG	0.73	N/A
Ticker research	View CYTK research	View SYRE research

Valuation

P/S Ratio

CYTK

126.04x

SYRE

6,680.42x

EV/FCF

SYRE

-34.84x

CYTK

-16.22x

Growth & revenue

Revenue Growth TTM

CYTK

-21.1%

Forward Revenue Growth

SYRE

231.1%

CYTK

183.7%

Profitability & performance

Gross Margin

CYTK

58.9%

SYRE

0.0%

ROE

SYRE

-2432.0%

CYTK

-13119.0%

FCF Yield %

SYRE

-2.8%

CYTK

-6.8%

52-Week Performance

SYRE

384.7%

CYTK

3.4%

Detailed metrics comparison

CYTK

Cytokinetics Inc

SYRE

Spyre Therapeutics Inc

Market Cap

CYTK$8.53B

SYRE$7.44B

Enterprise Value

CYTK$9.42B

SYRE$7.28B

Price

CYTK$62.91

SYRE$85.69

P/E Ratio

CYTKN/A

SYREN/A

P/S Ratio

CYTK126.04x

SYRE6,680.42x

EV/Sales

CYTK139.22x

SYRE0.00x

EV/EBITDA

CYTK1,193.30x

SYRE0.00x

P/B Ratio

CYTK83.67x

SYRE7.46x

P/FCF Ratio

CYTKN/A

SYREN/A

EV/FCF

CYTK-16.22x

SYRE-34.84x

PEG Ratio

CYTKN/A

SYREN/A

Forward P/E (NTM)

CYTKN/A

SYREN/A

Forward P/S (NTM)

CYTK33.61x

SYREN/A

Revenue (TTM)

CYTK$68M

SYRE$0

Revenue Growth (YoY)

CYTK-21.1%

SYREN/A

Forward Rev Growth

CYTK183.7%

SYRE231.1%

Gross Margin (TTM)

CYTK58.9%

SYRE0.0%

Operating Margin (TTM)

CYTK0.0%

SYRE0.0%

EBITDA Margin (TTM)

CYTK-1027.6%

SYRE0.0%

Net Margin (TTM)

CYTK-1321.1%

SYRE0.0%

FCF Margin (TTM)

CYTK-858.2%

SYREN/A

Net Income (TTM)

CYTK$-894M

SYRE$-179M

FCF (TTM)

CYTK$-581M

SYRE$-209M

EPS (TTM)

CYTK-$6.77

SYRE-$2.11

ROE (TTM)

CYTK-13119.0%

SYRE-2432.0%

ROA (TTM)

CYTK-5902.0%

SYRE-2223.0%

ROIC (TTM)

CYTK-1872.0%

SYRE-2432.0%

Cash

CYTK$255M

SYRE$162M

Debt

CYTK$1.15B

SYRE$0

Net Cash/Debt

CYTK$-892M

SYRE$162M

Current Ratio (TTM)

CYTK6.66x

SYRE18.53x

Quick Ratio (TTM)

CYTK6.56x

SYRE18.09x

Debt/Equity (TTM)

CYTK6.01x

SYRE0.00x

Debt/Assets (TTM)

CYTK0.0%

SYRE0.0%

Interest Coverage (TTM)

CYTKN/A

SYREN/A

Net Debt/EBITDA (TTM)

CYTK0.00x

SYRE0.00x

Beta

CYTK0.42

SYRE3.19

52W Performance

CYTK3.4%

SYRE384.7%

YTD Performance

CYTK1.9%

SYRE180.2%

% from 52W High

CYTK-28.8%

SYRE-22.2%

% from 52W Low

CYTK15.9%

SYRE385.5%

Asset Turnover (TTM)

CYTK0.04x

SYRE0.01x

FCF Yield (TTM)

CYTK-6.8%

SYRE-2.8%

Earnings Yield (TTM)

CYTK-10.5%

SYRE-2.4%

Dividend Yield (TTM)

CYTKN/A

SYREN/A

Rule of 40

CYTK-879.2

SYRE0.0

EV/GP/RG

CYTK0.73

SYREN/A

Ticker research

View CYTK research View SYRE research

Metric	CYTK Cytokinetics Inc	SYRE Spyre Therapeutics Inc
Market & Valuation
Market Cap	$8.53B	$7.44B
Enterprise Value	$9.42B	$7.28B
Price	$62.91	$85.69
P/E Ratio	N/A	N/A
P/S Ratio	126.04x	6,680.42x
EV/Sales	139.22x	0.00x
EV/EBITDA	1,193.30x	0.00x
P/B Ratio	83.67x	7.46x
P/FCF Ratio	N/A	N/A
EV/FCF	-16.22x	-34.84x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	33.61x	N/A
Revenue & Growth
Revenue (TTM)	$68M	$0
Revenue Growth (YoY)	-21.1%	N/A
Forward Rev Growth	183.7%	231.1%
Profitability
Gross Margin (TTM)	58.9%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-1027.6%	0.0%
Net Margin (TTM)	-1321.1%	0.0%
FCF Margin (TTM)	-858.2%	N/A
Net Income (TTM)	$-894M	$-179M
FCF (TTM)	$-581M	$-209M
EPS (TTM)	-$6.77	-$2.11
ROE (TTM)	-13119.0%	-2432.0%
ROA (TTM)	-5902.0%	-2223.0%
ROIC (TTM)	-1872.0%	-2432.0%
Financial Health
Cash	$255M	$162M
Debt	$1.15B	$0
Net Cash/Debt	$-892M	$162M
Current Ratio (TTM)	6.66x	18.53x
Quick Ratio (TTM)	6.56x	18.09x
Debt/Equity (TTM)	6.01x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.42	3.19
52W Performance	3.4%	384.7%
YTD Performance	1.9%	180.2%
% from 52W High	-28.8%	-22.2%
% from 52W Low	15.9%	385.5%
Efficiency & Yields
Asset Turnover (TTM)	0.04x	0.01x
FCF Yield (TTM)	-6.8%	-2.8%
Earnings Yield (TTM)	-10.5%	-2.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-879.2	0.0
EV/GP/RG	0.73	N/A
Ticker research	View CYTK research	View SYRE research